Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPS: Gemcitabine/cisplatin with or without sorafenib in advanced pancreatic cancer
2007-001781-32Phase 2Completed
- Sponsor
- Fondazione Giscad per la Ricerca sui Tumori
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sorafenib in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Fondazione Giscad per la Ricerca sui Tumori. Primary endpoint: Progression-free survival. Started Sep 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2007-001781-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001781-32.